The standardized Ginkgo biloba leaf extract (Gingium) is generally considered relevant for easing symptom clusters that may become intense or disruptive across therapeutic domains. The medication is commonly used to help with age-related cognitive impairment and peripheral circulatory issues.

Symptomatic Relief and Functional Support

Gingium is applied across domains where additional symptomatic support is needed in conditions presenting with localized discomfort and symptoms related to cognitive decline. The key therapeutic uses include the supportive management of chronic symptoms related to memory, concentration, and mental performance in older adults, and addressing symptoms of pain, cramping, and heaviness in the legs upon walking (intermittent claudication). The product may also assist with managing chronic tinnitus and vertigo in situations where patients experience these symptoms.

“The supportive benefit assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”

This application is relevant for managing symptoms that interfere with daily comfort, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations, and may be part of symptomatic management in situations where these issues create noticeable functional strain.

---

Quick Fact: Used for managing symptoms related to Intermittent Claudication

Regulatory References

1. European Medicines Agency (EMA) summary

Official Eligibility and Restrictions for Gingium

The regulatory documents for Gingium (Standardized Ginkgo Bilobae Foliorum Extract) strictly define the eligible patient population. The medicine is officially documented for use in Adults and Older People (Elderly). Use in children and adolescents under 18 years of age is not recommended due to insufficient supporting data.

---

Absolute Contraindications

Use of the medicine is strictly prohibited in the following populations:

• Pregnant women, due to the potential to impair platelet aggregation.
• Patients with a known hypersensitivity or allergy to the active substance or any excipients.

---

Special Warnings and Conditional Use

Certain conditions require specific precautions, defining restricted eligibility:

• Surgery: The medicine must be discontinued 3 to 4 days prior to any planned surgery or dental procedure.
• Bleeding Risk: Patients with a pathologically increased bleeding tendency or those taking anticoagulant/antiplatelet drugs require restricted use and caution.
• Epilepsy: Use requires a special warning in patients with epilepsy, as the onset of further seizures cannot be excluded.
• Lactation: Use during breastfeeding (lactation) is not recommended.

The official interaction profile for standardized Ginkgo biloba extract is defined by its potential to interact with agents that affect blood clotting and those that rely on specific metabolic pathways. A primary area of regulatory caution involves Pharmacodynamic Interactions related to hemostasis. The co-administration of anticoagulants, such as Warfarin, and antiplatelet drugs, including Aspirin and Clopidogrel, may influence their effect and increase the potential for bleeding. Regulatory documents state this combination requires adequate monitoring when the Ginkgo preparation is initiated, discontinued, or the dose is adjusted.

Furthermore, several Pharmacokinetic Interactions are documented. Co-use with the antiviral medicine Efavirenz is not recommended because the extract may induce the CYP3A4 enzyme, officially resulting in decreased plasma concentrations of Efavirenz. The extract is also documented as a potential P-glycoprotein (P-gp) inhibitor, which may lead to increased exposure of P-gp substrates like the anticoagulant Dabigatran etexilate; consequently, caution is advised. Separately, the maximum plasma concentration (C max) of Nifedipine has been shown in some individuals to increase upon co-administration. Due to the overall potential to increase bleeding, a specific timing rule is imposed: the product must be discontinued 3 to 4 days prior to surgery as a formal precaution. A final interaction note states that the onset of further seizures cannot be excluded in patients with epilepsy.

Vascular and Rheological Optimization

The standardized extract acts on the vascular system via a dual mechanism. Terpene Lactones (Ginkgolides) function as potent antagonists of the Platelet-Activating Factor ( PAF) Receptor, while Flavonoid Glycosides modulate the vascular endothelium. This action promotes local vasodilation and inhibits platelet aggregation, resulting in increased microcirculatory blood flow and elevated tissue perfusion. This mechanism integrates anti-thrombotic signaling and vasoactive modulation, leading to greater delivery of oxygen and nutrients to the tissue.

Cellular and Neurochemical Modulation

Flavonoid Glycosides act as potent scavengers of Reactive Oxygen Species ( ROS), which mitigate cellular damage. Concurrently, Bilobalide modulates ATP production in the Mitochondrial ATP Synthesis Pathway, and the extract reversibly inhibits the MAO-A enzyme. This combination of ROS neutralization and ATP production modulation results in stabilization of neuronal membrane integrity. MAO-A inhibition further modulates central nervous system signaling by altering the concentration of monoamine neurotransmitters.

Official Administration Protocol for Gingium

The use of Gingium, a standardized Ginkgo biloba leaf extract, is governed by official instructions outlining the proper administration protocol, not clinical advice. The product is supplied as a film-coated tablet intended strictly for oral use and must be swallowed whole with water.

The standard adult dosing regimen of the standardized dry extract is typically 240 mg per day. This amount is generally administered in one of two ways: either as a single dose once daily or divided into two 120 mg doses taken twice daily. To ensure proper administration, the tablets are consistently instructed to be taken after food.

For older adults, no specific dosage adjustment is required, and the standard adult regimen applies. Conversely, the product is not recommended for use in individuals under 18 years of age.

In terms of procedural administration over time, the course is typically initiated for a minimum of 8 weeks before a professional assessment of the effects. If symptomatic improvement is not evident after 3 months of continuous use, the treatment’s continuation should be professionally re-evaluated. If a dose is missed, a patient should not take a double dose to compensate, but should simply resume the schedule at the next usual time.

Gingium: Recent Clinical Evidence

Recent clinical research on standardized Ginkgo biloba extract (such as EGb 761, the basis for Gingium) has primarily focused on its effects in areas of cognitive function and peripheral blood flow.

---

Studies on Cognitive Outcomes

Research regarding the extract's effects on memory and cognitive decline presents mixed findings. Large, long-term studies, such as the Ginkgo Evaluation of Memory (GEM) Study, found that twice-daily administration over several years did not prevent or slow the progression of all-cause dementia in older adults with either normal cognition or mild cognitive impairment.

Conversely, several meta-analyses and randomized controlled trials focused on patients who already have mild-to-moderate dementia have explored an association with stabilization or slight improvement in some cognitive assessment scores (e.g., ADAS-Cog or MMSE) and neuropsychiatric symptoms, particularly with higher doses (240 mg/day) and long-term use (six months to one year).

---

Research on Circulation

Clinical trials have investigated the extract's use for intermittent claudication, which is pain in the legs caused by reduced blood flow in the arteries. Some smaller studies have suggested that the extract may be associated with improved pain-free walking distance; however, other large trials have not consistently shown this benefit.

Research using quantitative imaging techniques has also explored the extract’s effects on cerebral blood flow (CBF) in healthy elderly individuals, with some pilot studies observing a small, statistically significant increase in global CBF. However, large-scale, definitive trials confirming these circulatory effects are limited.

Common questions about Gingium (FAQ)

Q: What is the active ingredient in Gingium?

Gingium contains a refined extract from the leaves of the Ginkgo biloba tree. According to the official product information, this is a standardized dry extract, which means it consistently provides a specific, measurable amount of the active components.

Q: What is Gingium used for?

Regulatory documents indicate that Gingium is used to help improve age-related cognitive impairment and quality of life in mild dementia. It is also officially recognized for relieving symptoms of mild blood circulation disorders in the limbs and for supportive treatment of ringing in the ears (tinnitus) and dizziness of vascular or unknown origin.

Q: Can Gingium be used for tinnitus (ringing in the ears)?

According to the official product information, Gingium is indicated as a supportive treatment for tinnitus, which is the perception of ringing or noise in the ears. This use applies specifically when the tinnitus is due to vascular causes or causes that are currently unknown. Official product information specifies that Gingium is intended as a supportive measure in managing this condition.

Q: How long does it take for Gingium to work?

Regulatory documents state that for conditions like mild dementia or age-related cognitive impairment, the therapeutic benefit of Gingium may appear after a period of 8 weeks of continuous use. For relief of mild circulation disorders, an improvement is typically expected after a treatment duration of approximately 6 weeks. The required treatment duration varies based on the specific condition being treated, as detailed in the official product information.

Q: Can I use Gingium to improve memory and concentration?

Official information indicates that Gingium is used to help improve age-related cognitive impairment, which includes difficulties with memory and concentration. Its documented use is limited to supporting cognitive function in the context of age-related impairment associated with mild dementia, according to regulatory approvals.

Q: What is the function of the Ginkgo extract in Gingium?

Official product information suggests the standardized Ginkgo extract supports blood circulation, especially microcirculation in the brain and extremities. It may also possess antioxidant properties and is believed to contribute to the documented improvements in cognitive function and circulation-related symptoms.

Q: Is Gingium available without a prescription?

According to the official German regulatory source, Gingium is classified as a medicine that is subject to mandatory pharmacy dispensing (Apothekenpflichtig). While it does not require a doctor's prescription, it must be purchased directly from a pharmacy.

The official storage and disposal requirements for Gingium (Standardized Ginkgo Biloba Extract) are established to maintain product quality and ensure safety.

Mandatory Storage Conditions

Storage Requirement	Specification (Regulatory Labeling)
Temperature	Do not store above 25 C or 30 C; Do not freeze.
Protection	Store in the original container/package and protect from moisture.
Accessibility	Keep out of the sight and reach of children.

---

Official Disposal Rules

Unused or expired Gingium must not be disposed of via wastewater or household waste. Consult a pharmacist or local waste disposal company for proper disposal procedures in accordance with applicable environmental regulations.